Strategic Transformation of the Market of Hepatitis C Treatments

Problem

Ground-breaking therapeutic innovations for viral hepatitis have not translated into widespread access for the overwhelming majority of people with HCV.

Proposed Solution

Search for a new pan-genotypic affordable regimen, and increase access to care and treatment for HCV patients in key LMICs using a public health approach that generates evidence for (simplified) treatment, innovative models of care and scale-up of efforts, ultimately leading to a ‘test and cure’ strategy.

Potential Impact

- Reduce morbidity and mortality in MSF projects & DNDi studies, curing 12,000 patients over 3 years in Cambodia, Malaysia, South Africa, Thailand, Ukraine, Argentina, and Vietnam
- Overcome IP, regulatory, pricing and other barriers to improve access to and affordability of HCV treatment in LMICs.

Viability

- Creates a new public health model for extending access to more patients

Risk Mitigation

- Builds upon proven experience; directly engages the field

Scalability

- Scales up treatment and number of patients; if successful, model of care can be replicated for other disease areas

Area/Type: Medical Research and Development; Large Scale
Sponsor/Support: OC Paris / OC Geneva
Length/Project Status: 3.5 years; ONGOING